NR1H4 and metabolic dysfunction-associated steatotic liver disease: Activation of FXR may serve as a potential therapeutic target for preventing NAFLD‐related hepatocellular carcinoma (HCC), rather than an effective treatment for patients in the early stages of NAFLD.